Journal of Clinical Oncology, Vol 15, 987-993, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation

FM Muggia, JD Hainsworth, S Jeffers, P Miller, S Groshen, M Tan, L Roman, B Uziely, L Muderspach, A Garcia, A Burnett, FA Greco, CP Morrow, LJ Paradiso and LJ Liang
Department of Radiology, University of Southern California-Norris Comprehensive Cancer Center, Los Angeles, USA. franco.muggia@ccmail.med.nyu.edu

PURPOSE: A phase II study of liposomal doxorubicin was conducted in patients with ovarian cancer who failed to respond to platinum- and paclitaxel-based regimens. Liposomal doxorubicin was selected as a result of its superior activity against ovarian cancer xenografts relative to free doxorubicin and activity in refractory ovarian cancer patients that was noted during the phase I study. PATIENTS AND METHODS: Thirty-five consecutive patients were accrued in two institutions (22 in one and 13 in the other). All had progressive disease after either cisplatin or carboplatin and paclitaxel, or at least one platinum-based and one paclitaxel-based regimen. Patients received intravenous (I.V.) liposomal doxorubicin 50 mg/m2 every 3 weeks with a dose reduction to 40 mg/m2 in the event of grade 3 or 4 toxicities, or a lengthening of the interval to 4 weeks (and occasionally to 5 weeks) with persistence of grade 1 or 2 toxicities beyond 3 weeks. RESULTS: Nine clinical responses (one complete response [CR], eight partial responses [PRs]) were observed in 35 patients (25.7%), with seven of these having been confirmed by two consecutive computed tomographic (CT) measurements. The median progression-free survival was 5.7 months with an overall survival of 1.5 to 24+ months (median, 11 months). Although 13 patients experienced grade 3 or 4 nonhematologic skin and mucosal toxicities (either hand-foot syndrome or stomatitis), with dose modifications, the treatment was very well tolerated. Nausea that was clearly attributable to the drug, hair loss, extravasation necrosis, or decreases in ejection fraction did not occur. CONCLUSION: Liposomal doxorubicin has substantial activity against ovarian cancer refractory to platinum and paclitaxel. The responses achieved with liposomal doxorubicin were durable and maintained with minimal toxicity. This liposomal formulation should be evaluated further in combination with other drugs in less refractory patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T.-H. CHOW, Y.-Y. LIN, J.-J. HWANG, H.-E. WANG, Y.-L. TSENG, S.-J. WANG, R.-S. LIU, W.-J. LIN, C.-S. YANG, and G. TING Improvement of Biodistribution and Therapeutic Index via Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/luc Xenografted Mouse Model Anticancer Res, June 1, 2009; 29(6): 2111 - 2120. [Abstract] [Full Text] [PDF]

				A. MARTSCHICK, J. SEHOULI, A. PATZELT, H. RICHTER, U. JACOBI, G. OSKAY-OZCELIK, W. STERRY, and J. LADEMANN The Pathogenetic Mechanism of Anthracycline-induced Palmar-plantar Erythrodysesthesia Anticancer Res, June 1, 2009; 29(6): 2307 - 2313. [Abstract] [Full Text] [PDF]

				P. J. Hoskins Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy J. Clin. Oncol., March 20, 2009; 27(9): 1355 - 1358. [Full Text] [PDF]

				N. Katsumata, Y. Fujiwara, T. Kamura, T. Nakanishi, M. Hatae, D. Aoki, K. Tanaka, H. Tsuda, S. Kamiura, K. Takehara, et al. Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 777 - 785. [Abstract] [Full Text] [PDF]

				A. Lo, C.-T. Lin, and H.-C. Wu Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery Mol. Cancer Ther., March 1, 2008; 7(3): 579 - 589. [Abstract] [Full Text] [PDF]

				G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann Current Management Strategies for Ovarian Cancer Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770. [Abstract] [Full Text] [PDF]

				S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]

				E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann. Onc., April 1, 2007; 18(4): 716 - 721. [Abstract] [Full Text] [PDF]

				Y. Fujisaka, A. Horiike, T. Shimizu, N. Yamamoto, Y. Yamada, and T. Tamura Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 768 - 774. [Abstract] [Full Text] [PDF]

				D. Pectasides, E. Pectasides, and T. Economopoulos Fallopian Tube Carcinoma: A Review Oncologist, September 1, 2006; 11(8): 902 - 912. [Abstract] [Full Text] [PDF]

				D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919. [Abstract] [Full Text] [PDF]

				H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30. [Abstract] [PDF]

				P. G. Rose Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer Oncologist, March 1, 2005; 10(3): 205 - 214. [Abstract] [Full Text] [PDF]

				D. Katsaros, M. V. Oletti, I. A. Rigault de la Longrais, A. Ferrero, A. Celano, S. Fracchioli, M. Donadio, R. Passera, L. Cattel, and C. Bumma Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma Ann. Onc., February 1, 2005; 16(2): 300 - 306. [Abstract] [Full Text] [PDF]

				T. J. Herzog Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression? Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449. [Abstract] [Full Text] [PDF]

				A. M. Keller, R. G. Mennel, V. A. Georgoulias, J.-M. Nabholtz, A. Erazo, A. Lluch, C. L. Vogel, M. Kaufmann, G. von Minckwitz, I. C. Henderson, et al. Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer J. Clin. Oncol., October 1, 2004; 22(19): 3893 - 3901. [Abstract] [Full Text] [PDF]

				S. Swenson, F. Costa, R. Minea, R. P. Sherwin, W. Ernst, G. Fujii, D. Yang, and F. S. Markland Jr. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression Mol. Cancer Ther., April 1, 2004; 3(4): 499 - 511. [Abstract] [Full Text] [PDF]

				P. Sapra, E. H. Moase, J. Ma, and T. M. Allen Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab' Fragments Clin. Cancer Res., February 1, 2004; 10(3): 1100 - 1111. [Abstract] [Full Text] [PDF]

				P. Gilbar Palmar-plantar erythrodysesthesia Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 137 - 150. [Abstract] [PDF]

				T. Voskoglou-Nomikos, J. L. Pater, and L. Seymour Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models Clin. Cancer Res., September 15, 2003; 9(11): 4227 - 4239. [Abstract] [Full Text] [PDF]

				R. Tambaro, S. Greggi, R. V. Iaffaioli, A. Rossi, C. Pisano, L. Manzione, E. Ferrari, M. Di Maio, F. Iodice, G. Casella, et al. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer Ann. Onc., September 1, 2003; 14(9): 1406 - 1411. [Abstract] [Full Text] [PDF]

				A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N. M. Rafique, C. R. Alving, and F. M. Muggia Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil(R)): possible role in hypersensitivity reactions Ann. Onc., September 1, 2003; 14(9): 1430 - 1437. [Abstract] [Full Text] [PDF]

				G. J. R. Charrois and T. M. Allen Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1058 - 1067. [Abstract] [Full Text] [PDF]

				M. A. Bookman Developmental Chemotherapy and Management of Recurrent Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167. [Abstract] [Full Text] [PDF]

				F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice Cancer Res., January 1, 2003; 63(1): 86 - 92. [Abstract] [Full Text] [PDF]

				F. M. Muggia, J. A. Blessing, J. Sorosky, and G. C. Reid Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group Study J. Clin. Oncol., May 1, 2002; 20(9): 2360 - 2364. [Abstract] [Full Text] [PDF]

				R. F. Ozols Recurrent Ovarian Cancer: Evidence-Based Treatment J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163. [Full Text] [PDF]

				V. Dieras, P. Bougnoux, T. Petit, P. Chollet, P. Beuzeboc, C. Borel, F. Husseini, A. Goupil, P. Kerbrat, J. L. Misset, et al. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin {+/-} taxane-pretreated ovarian cancer patients Ann. Onc., February 20, 2002; 13(2): 258 - 266. [Abstract] [Full Text] [PDF]

				V. H. C. Bramwell, D. Morris, D. S. Ernst, I. Hings, M. Blackstein, P. M. Venner, E. I. Ette, M. W. Harding, A. Waxman, and G. D. Demetri Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma Clin. Cancer Res., February 1, 2002; 8(2): 383 - 393. [Abstract] [Full Text] [PDF]

				O. Lyass, A. Hubert, and A. A. Gabizon Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies Clin. Cancer Res., October 1, 2001; 7(10): 3040 - 3046. [Abstract] [Full Text] [PDF]

				A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan J. Clin. Oncol., July 15, 2001; 19(14): 3312 - 3322. [Abstract] [Full Text] [PDF]

				R. Banerjee Liposomes: Applications in Medicine J Biomater Appl, July 1, 2001; 16(1): 3 - 21. [Abstract] [PDF]

				M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.-F. Heron, G. Bolis, H. Malmstrom, et al. Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer J. Clin. Oncol., April 1, 2001; 19(7): 1893 - 1900. [Abstract] [Full Text] [PDF]

				I. A. Malik Altretamine is an Effective Palliative Therapy of Patients with Recurrent Epithelial Ovarian Cancer Jpn. J. Clin. Oncol., February 1, 2001; 31(2): 69 - 73. [Abstract] [Full Text] [PDF]

				K. J. Harrington, S. Mohammadtaghi, P. S. Uster, D. Glass, A. M. Peters, R. G. Vile, and J. S. W. Stewart Effective Targeting of Solid Tumors in Patients With Locally Advanced Cancers by Radiolabeled Pegylated Liposomes Clin. Cancer Res., February 1, 2001; 7(2): 243 - 254. [Abstract] [Full Text]

				G. Frykman, G. Williams, R. Pazdur, and A. N. Gordon Conflicting Phase II Efficacy Data for Doxil J. Clin. Oncol., January 15, 2001; 19(2): 596 - 597. [Full Text] [PDF]

				M. Lotem, A. Hubert, O. Lyass, M. A. Goldenhersh, A. Ingber, T. Peretz, and A. Gabizon Skin Toxic Effects of Polyethylene Glycol-Coated Liposomal Doxorubicin Arch Dermatol, December 1, 2000; 136(12): 1475 - 1480. [Abstract] [Full Text] [PDF]

				P. J. Stiff, J. Veum-Stone, H. M. Lazarus, L. Ayash, J. R. Edwards, A. Keating, J. P. Klein, D. J. Oblon, T. C. Shea, S. Thome, et al. High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report Ann Intern Med, October 3, 2000; 133(7): 504 - 515. [Abstract] [Full Text] [PDF]

				A. N. Gordon, C. O. Granai, P. G. Rose, J. Hainsworth, A. Lopez, C. Weissman, R. Rosales, and T. Sharpington Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer J. Clin. Oncol., September 17, 2000; 18(17): 3093 - 3100. [Abstract] [Full Text] [PDF]

				C. F. Verschraegen, T. Sittisomwong, A. P. Kudelka, E. d. P. Guedes, M. Steger, T. Nelson-Taylor, M. Vincent, R. Rogers, E. N. Atkinson, and J. J. Kavanagh Docetaxel for Patients With Paclitaxel-Resistant Mullerian Carcinoma J. Clin. Oncol., July 14, 2000; 18(14): 2733 - 2739. [Abstract] [Full Text] [PDF]

				K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos, P. S. Uster, R. G. Vile, and J. S. W. Stewart Pegylated Liposomes Have Potential as Vehicles for Intratumoral and Subcutaneous Drug Delivery Clin. Cancer Res., June 1, 2000; 6(6): 2528 - 2537. [Abstract] [Full Text]

				E. T. M. Dams, P. Laverman, W. J. G. Oyen, G. Storm, G. L. Scherphof, J. W. M. van der Meer, F. H. M. Corstens, and O. C. Boerman Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 1071 - 1079. [Abstract] [Full Text]

				M. Markman and M. A. Bookman Second-Line Treatment of Ovarian Cancer Oncologist, February 1, 2000; 5(1): 26 - 35. [Abstract] [Full Text]

				D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]

				M. I. Koukourakis, S. Koukouraki, A. Giatromanolaki, S. C. Archimandritis, J. Skarlatos, K. Beroukas, J. G. Bizakis, G. Retalis, N. Karkavitsas, and E. S. Helidonis Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3512 - 3521. [Abstract] [Full Text] [PDF]

				P. K. Working, M. S. Newman, T. Sullivan, and J. Yarrington Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1128 - 1133. [Abstract] [Full Text]

				M. A. Bookman Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy Oncologist, April 1, 1999; 4(2): 87 - 94. [Abstract] [Full Text]

				S. A. Cannistra Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited J. Clin. Oncol., March 1, 1999; 17(3): 741 - 741. [Full Text] [PDF]

				A. du Bois, H. J. Luck, T. Bauknecht, W. Meier, B. Richter, W. Kuhn, J. Quaas, and J. Pfisterer First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group J. Clin. Oncol., January 1, 1999; 17(1): 46 - 46. [Abstract] [Full Text] [PDF]

				M Amantea, M S Newman, T M Sullivan, A Forrest, and P K Working Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs Human and Experimental Toxicology, January 1, 1999; 18(1): 17 - 26. [Abstract] [PDF]